Yeast-derived nanoparticles remodel the immunosuppressive microenvironment in tumor and tumor-draining lymph nodes to suppress tumor growth

Abstract

Microbe-based cancer immunotherapy has recently emerged as a hot topic for cancer treatment. However, serious limitations remain including infection associated side-effect and unsatisfactory outcomes in clinic trials. Here, we fabricate different sizes of nano-formulations derived from yeast cell wall (YCW NPs) by differential centrifugation. The induction of anticancer immunity of our formulations appears to inversely correlate with their size due to the ability to accumulate in tumor-draining lymph node (TDLN). Moreover, we use a percolation model to explain their distribution behavior toward TDLN. The abundance and functional orientation of each effector component are significantly improved not only in the microenvironment in tumor but also in the TDLN following small size YCW NPs treatment. In combination with programmed death-ligand 1 (PD-L1) blockade, we demonstrate anticancer efficiency in melanoma-challenged mice. We delineate potential strategy to target immunosuppressive microenvironment by microbe-based nanoparticles and highlight the role of size effect in microbe-based immune therapeutics.

Recent Advances in Chitosan and its Derivatives in Cancer Treatment

“…It is a promising cancer treatment method, with the advantages of cooperating two kinds of treatment mechanism ( Nowak and Lesterhuis, 2014 ). The very recent studies demonstrated that nanoparticles could remodel immunosuppressive tumor microenvironment, holding great promise for chemoimmunotherapy ( Xu et al, 2022 ). Moreover, nanobased delivery systems have exhibited excellent properties, such as targeted drug delivery, tumor microenvironment modulation, targeted and time-controlled release of conjugate drugs, so as to improve the pharmacokinetics and stability of drugs in vivo .…”

Gut microbiome in gastrointestinal cancer: a friend or foe?

“…The combination of yeast-derived nanoparticles and PD-L1 antibody has shown a superior antitumor effect in CRC. It can not only effectively eliminate in situ tumor, but also inhibit the growth of distal spreading cancer cells [171].…”

Microparticles: biogenesis, characteristics and intervention therapy for cancers in preclinical and clinical research

“…Microorganisms contain some compositions that are considered as PAMPs by immune system. Wang et al incubated yeast cells in NaOH at 80 °C for 1 h, followed by sonication and differential centrifugation to obtain EVs with different sizes [ 78 ]. These EVs contained ~ 88.2% β-glucan, 2.9% proteins and 8.9% other materials, and these activated DCs through Dectin-1/Syk and TLR2/MyD88 pathways.…”